{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:42:12Z","timestamp":1793781732925,"version":"4.6.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:00:00Z","timestamp":1381363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.pnpbp.2013.10.003","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T07:01:40Z","timestamp":1381561300000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Is schizophrenia a dopamine supersensitivity psychotic reaction?"],"prefix":"10.1016","volume":"48","author":[{"given":"Mary V.","family":"Seeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Seeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2013.10.003_bb0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S0033291708004819","article-title":"Hallucinations and two types of free-recall intrusion in schizophrenia","volume":"39","author":"Br\u00e9bion","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.schres.2006.03.042","article-title":"D2\/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia","volume":"85","author":"Buchsbaum","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.schres.2005.02.004","article-title":"Obsessive compulsive symptoms in schizophrenia: frequency and clinical features","volume":"76","author":"Byerly","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0020","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/mds.23050","article-title":"Motor behavior abnormalities in drug naive patients with schizophrenia spectrum disorders","volume":"25","author":"Campos","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1523\/JNEUROSCI.07-05-01352.1987","article-title":"Dopamine D2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand","volume":"7","author":"Charuchinda","year":"1987","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(91)90050-2","article-title":"Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment","volume":"5","author":"Chouinard","year":"1990","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0040","series-title":"Lancet II","first-page":"99","article-title":"Schizophrenia as dopamine-deficiency disease","author":"Chouinard","year":"1978"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1744-6163.1996.tb00502.x","article-title":"The symbolic and literal in schizophrenic language","volume":"32","author":"Chouvardas","year":"1996","journal-title":"Perspect Psychiatr Care"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0050","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/00332747.1992.11024600","article-title":"Positive withdrawal and the quest for meaning: the reconstruction of experience among schizophrenics","volume":"55","author":"Corin","year":"1992","journal-title":"Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.euroneuro.2011.03.004","article-title":"Density of striatal D2 receptors in untreated first-episode psychosis: an I(123)-IBZM SPECT study","volume":"21","author":"Corripio","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0060","first-page":"267","article-title":"Traitement des \u00e9tats d'excitation et d'agitation par une m\u00e9thode m\u00e9dicamenteuse d\u00e9riv\u00e9e de l'hibernith\u00e9rapie","volume":"110","author":"Delay","year":"1952","journal-title":"Ann Med Psychol (Paris)"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1353\/ppp.0.0139","article-title":"Adolf Meyer's psychobiology and the challenge for biomedicine","volume":"14","author":"Double","year":"2007","journal-title":"Philos Psychiatr Psychol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.schres.2010.04.006","article-title":"Conceptual combination and language in schizophrenia","volume":"120","author":"Elvev\u00e5g","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archpsyc.1990.01810150013003","article-title":"D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride","volume":"47","author":"Farde","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/oxfordjournals.schbul.a007018","article-title":"Auditory hallucinations, source monitoring, and the belief that \u201cvoices\u201d are real","volume":"29","author":"Garrett","year":"2003","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0325","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/15563658408992586","article-title":"Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity","volume":"22","author":"Giannini","year":"1984","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00045391-200007060-00008","article-title":"Acute ketamine intoxication treated by haloperidol: a preliminary study","volume":"7","author":"Giannini","year":"2000","journal-title":"Am J Ther"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0095","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/npp.2008.199","article-title":"The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study","volume":"34","author":"Graff-Guerrero","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0924-977X(94)00127-W","article-title":"Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study","volume":"5","author":"Hall","year":"1995","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III \u2014 the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"issue":"8","key":"10.1016\/j.pnpbp.2013.10.003_bb0110","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0115","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0b013e31828ea95c","article-title":"Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis","volume":"33","author":"Iyo","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0120","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1176\/appi.ajp.162.5.939","article-title":"Evidence for onset of antipsychotic effects within the first 24hours of treatment","volume":"162","author":"Kapur","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0125","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.biopsych.2010.05.027","article-title":"Striatal and extrastriatal dopamine D2\/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography","volume":"68","author":"Kegeles","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.neuron.2006.01.023","article-title":"Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning","volume":"49","author":"Kellendonk","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2013.01.008","article-title":"Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis","volume":"145","author":"Kimura","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0140","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","article-title":"Provocative tests with psychostimulant drugs in schizophrenia","volume":"91","author":"Lieberman","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.pnpbp.2013.10.003_bb0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/0964704X.2012.678199","article-title":"History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia","volume":"22","author":"Madras","year":"2013","journal-title":"J Hist Neurosci"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.conb.2013.06.007","article-title":"Neurite pruning and neuronal cell death: spatial regulation of shared destruction programs","author":"Maor-Nof","year":"2013","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.10.003_bb0165","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1176\/ajp.78.3.355","article-title":"Constructive formulation of schizophrenia","volume":"78","author":"Meyer","year":"1922","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0170","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0006-3223(93)90044-E","article-title":"Loss of striatal cholinergic neurons as a basis of tardive and l-dopa-induced dyskinesias, and neuroleptic-induced supersensitivity psychosis","volume":"34","author":"Miller","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0175","series-title":"The human central nervous system","first-page":"626","author":"Nieuwenhuys","year":"2008"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0180","series-title":"American madness: the rise and fall of dementia praecox","author":"Noll","year":"2011"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0185","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1017\/S0033291708004716","article-title":"Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review","volume":"39","author":"Pappa","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0190","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0195","doi-asserted-by":"crossref","first-page":"36625","DOI":"10.1074\/jbc.M110.159954","article-title":"The dopamine D1\u2013D2 receptor heteromer localizes in dynorphin\/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia","volume":"285","author":"Perreault","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0200","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis","volume":"91","author":"Reith","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0205","article-title":"Can antipsychotic treatment contribute to drug addiction in schizophrenia?","author":"Samaha","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2013.10.003_bb0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.schres.2008.12.024","article-title":"Schizophrenia model of elevated D2High receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2High","volume":"109","author":"Seeman","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0215","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0220","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/JCP.0b013e318248daaa","article-title":"Comment on \u201cA multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia\u201d by Kinon, B.J. et al.","volume":"32","author":"Seeman","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/syn.20987","article-title":"Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans","volume":"66","author":"Seeman","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0230","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.euroneuro.2013.06.005","article-title":"Schizophrenia and dopamine receptors","volume":"23","author":"Seeman","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0235","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pnpbp.2013.07.006","article-title":"Are dopamine D2 receptors out of control in psychosis?","volume":"46","author":"Seeman","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscychresns.2013.09.013","article-title":"Schizophrenia thalamus imaging: low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and less presynaptic terminals","author":"Seeman","year":"2013","journal-title":"Psychiatry Res: Neuroimaging"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0245","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.02.011","article-title":"Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia","volume":"44","author":"Seeman","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0250","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.72.11.4376","article-title":"Brain receptors for antipsychotic drugs and dopamine: direct binding assays","volume":"72","author":"Seeman","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pnpbp.2013.10.003_bb0255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/syn.890010503","article-title":"Human brain dopamine receptors in children and aging adults","volume":"1","author":"Seeman","year":"1987","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pnpbp.2013.10.003_bb0260","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0893-133X(87)90004-2","article-title":"Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases","volume":"1","author":"Seeman","year":"1987","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.pnpbp.2013.10.003_bb0265","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/syn.20647","article-title":"Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil","volume":"63","author":"Seeman","year":"2009","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.pnpbp.2013.10.003_bb0270","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0275","series-title":"243rd Amer Chem Soc meeting, San Diego, CA","article-title":"Development of high affinity, highly selective agonist ligands for positron emission tomography imaging of the dopamine D2 receptor","author":"Sromek","year":"2011"},{"issue":"5","key":"10.1016\/j.pnpbp.2013.10.003_bb0280","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/schbul\/sbr006","article-title":"Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis","volume":"38","author":"Tadokoro","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0285","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1017\/S1461145703003699","article-title":"Decreased thalamic D2\/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457","volume":"6","author":"Talvik","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0290","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pscychresns.2006.05.009","article-title":"Dopamine D2 receptor binding in drug-na\u00efve patients with schizophrenia examined with raclopride-C11 and positron emission tomography","volume":"148","author":"Talvik","year":"2006","journal-title":"Psychiatry Res: Neuroimaging"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0295","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00406-006-0649-3","article-title":"Midbrain dopamine D2\/3 receptor binding in schizophrenia","volume":"256","author":"Tuppurainen","year":"2006","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0300","series-title":"Neuropsychopharmacology, Proc 5th Collegium Int Neuropsychopharmacologicum","first-page":"321","article-title":"The significance of dopamine-receptor blockade for the action of neuroleptic drugs","author":"Van Rossum","year":"1967"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0305","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/schbul\/sbp016","article-title":"Substance use disorders in schizophrenia \u2014 clinical implications of comorbidity","volume":"35","author":"Volkow","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1756-6606-3-25","article-title":"Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization","volume":"3","author":"Wang","year":"2010","journal-title":"Mol Brain"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0315","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1176\/appi.ajp.161.6.1016","article-title":"Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia","volume":"161","author":"Yasuno","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.003_bb0320","article-title":"Throughout history, defining schizophrenia has remained a challenge (timeline)","author":"Yuhas","year":"2013","journal-title":"Sci Am Mind"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613002194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613002194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T19:13:26Z","timestamp":1564514006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584613002194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":64,"alternative-id":["S0278584613002194"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.10.003","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is schizophrenia a dopamine supersensitivity psychotic reaction?","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}